Peripheral Arterial Disease (PAD) Therapeutics - Global Strategic Business Report

Description: The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for Peripheral Arterial Disease (PAD) Therapeutics in US$ Million.

Company profiles are primarily based on public domain information including company URLs. The report profiles 23 companies including many key and niche players such as -

AstraZeneca Plc
Bayer HealthCare Pharmaceuticals
Bristol-Myers Squibb Company
Merck & Co., Inc.
Proteon Therapeutics, Inc.

Contents:

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW
PAD
A Prelude
PAD Statistics
Table 1: Prevalence of Peripheral Artery Disease by Age Group and Gender (includes corresponding Graph/Chart)
Critical Limb Ischemia
An Insight
High Costs
A Cause of Concern

2. PAD THERAPEUTICS
Anti-Platelet Drugs: Spearheading the Battle against PAD
Key Drugs for Arterial Disease
Clopidogrel (Plavix)
Prasugrel (Effient)
Ticagrelor (Brilinta)
Vorapaxar (Zontivity)
Dual Antiplatelet Therapy (DAPT) for PAD
Entry of Generics Tones Down Growth in Major Markets
Brilinta Fails to Meet Expectations in EUCLID Trial
Xarelto Pins Hope on COMPASS and VOYAGER trials
Other Pipeline Drugs for Peripheral Arterial Disease (PAD)
Cholesterol-Lowering Drugs: A Key Weapon in the Anti-PAD Arsenal

3. MACRO GROWTH DRIVERS
Aging
A Key Driver
Table 2: Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)
Table 3: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in ‘000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart)
Table 4: Life Expectancy at Age 60 and 80 Years (2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart)
High Diabetes Incidence Worldwide: Key Market Opportunity for PAD Therapeutics
Table 5: Worldwide Prevalence of Diabetes: Number of Adults (20-79) with Diabetes in 2015 and 2040 (includes corresponding Graph/Chart)
Table 6: Global Prevalence of Diabetes Number of Adults Diagnosed with Diabetes (in Million) by Gender for 2015 & 2040 (includes corresponding Graph/Chart)

4. PERIPHERAL ARTERIAL DISEASE (PAD)
AN OVERVIEW
Peripheral Arterial Disease: Understanding the Stealthy Peril
Causes of PAD
Tobacco Use
Diabetes
Dyslipidemia
Hypertension
Causes of PAD in Lower Extremities
Atherosclerosis
Blood Clotting
Link Established between Depression and PAD
Ethyl-EPA Intake Proves Favorable for PAD Sufferers
PAD Risk Factors
Symptoms of PAD
Claudication
Rest Pain
Other Symptoms
Prognosis of PAD
Diagnosis of PAD
Ankle Brachial Index (ABI)
Ankle-Brachial Index and Associated Severity of Peripheral Arterial Disease
Magnetic Resonance Angiography (MRA) and CT Scan
Control of PAD
Classification of PAD Severity
Methods for Avoiding PAD Complications
Treatment Options for Peripheral Arterial Disease
A General Perspective
Lifestyle Changes
Surgery
Stenting
Artery Bypass Grafting
Atherectomy
Breakthrough Atherectomy Device
Amputation
Table 7: Leading PAD Treatment Approaches (2016): Percentage Share Breakdown of Number of Procedures for Atherectomy, Amputation, Bypass Surgery, and PTA/Stenting Procedures (includes corresponding Graph/Chart)
Medication
Hopes Pinned on Stem Cell Therapy to Revolutionize PAD Treatment
Placenta-derived Stem Cell Therapy: A Promising Treatment for PAD

5. COMPANIES INTO GENE THERAPY FOR PAD
AnGes MG, Inc. (Japan)
Athersys, Inc. (US)
Betagenon AB (Sweden)
CardioVascular BioTherapeutics, Inc. (US)
Celgene Corporation (US)
ID Pharma Co., Ltd. (Japan)
miRagen Therapeutics, Inc. (US)
Multi Gene Vascular Systems Ltd (Israel)
ViroMed Co. Ltd. (Korea)

6. CLINICAL STUDIES/CORPORATE INITIATIVES
AstraZeneca Announces Results of EUCLID Trial
USPTO Extends Patent Term for Bayer’s Rivaroxaban
Bayer and Janssen Expand Clinical Development Programme for Rivaroxaban
FDA Approves Merck’s Zontivity

7. FOCUS ON SELECT GLOBAL PLAYERS
AstraZeneca Plc. (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)

8. GLOBAL MARKET PERSPECTIVE
Table 8: World Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 9: World Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 10: World 14-Year Perspective for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

III. MARKET
1. THE UNITED STATES
A. Market Analysis
High PAD Incidence Drives Market
Table 11: Prevalence of Peripheral Arterial Disease by Age Group, Ethnicity, and Gender (2015)
Endovascular Intervention
A Review
Table 12: Volume Percentage Change in Interventional Procedures Performed in the US (2006-2014) (includes corresponding Graph/Chart)
Costs Associated with PAD Treatment
Generics Steal Market Share from Plavix
Aging Population Statistics & Diabetes Statistics: Key Opportunity Indicators
Table 13: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
Table 14: Diabetes and Population Statistics in North America and Caribbean Region (2015 & 2040) (includes corresponding Graph/Chart)
Table 15: Diabetes Statistics in the US (2015) Number of Adults with Diabetes (in 000s), Number of Adults with Undiagnosed Diabetes (in 000s), Diabetes Prevalence (%) and Number of Diabetes-Related Deaths (in ‘000s)
Clinical Studies/Product Approvals/Corporate Developments
Select Key Players
B. Market Analytics
Table 16: US Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 17: US Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

2. CANADA
A. Market Analysis
Measures to Increase PAD Awareness

B. Market Analytics

Table 18: Canadian Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 19: Canadian Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. JAPAN

A. Market Analysis

Table 20: Aging Population in Japan (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)

Select Key Players

B. Market Analytics

Table 21: Japanese Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 22: Japanese Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. EUROPE

A. Market Analysis

Plavix® Faces Generic and Branded Competition in Europe

B. Market Analytics

Table 23: European Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region/Country

France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 24: European Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region/Country

France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 25: European 14-Year Perspective for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region/Country

Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of European Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4a. FRANCE

A. Market Analysis

Sanofi

A Leading French Player

B. Market Analytics

Table 26: French Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 27: French Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4b. GERMANY

A. Market Analysis

Clinical Studies

Select Players

B. Market Analytics

Table 28: German Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 29: German Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4c. ITALY

Market Analysis

Table 30: Italian Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding...
Table 31: Italian Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM
A. Market Analysis
Clinical Studies
AstraZeneca Plc: Key UK-Based Global Player
B. Market Analytics
Table 32: UK Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 33: UK Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4e. SPAIN
A. Market Analysis
Table 34: Spanish Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 35: Spanish Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4f. REST OF EUROPE
A. Market Analysis
Select Key Player
B. Market Analytics
Table 36: Rest of European Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 37: Rest of European Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC
A. Market Analysis
Table 38: Asia-Pacific Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region/Country
China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 39: Asia-Pacific Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region/Country
China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 40: Asia-Pacific 14-Year Perspective for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region/Country
Percentage Breakdown of Dollar Sales for China and Rest of Asia-Pacific Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5a. CHINA
A. Market Analysis
Table 41: Chinese Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 42: Chinese Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5b. REST OF ASIA-PACIFIC
A. Market Analysis
India
Key Player
B. Market Analytics
Table 43: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes
corresponding Graph/Chart)
Table 44: Rest of Asia-Pacific Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6. LATIN AMERICA
Market Analysis
Table 45: Latin American Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 46: Latin American Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

7. REST OF WORLD
A. Market Analysis
   Current and Future Analysis
B. Market Analytics
Table 47: Rest of World Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 48: Rest of World Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 23 (including Divisions/Subsidiaries 25)
The United States (9)
Canada (1)
Japan (2)
Europe (7)
   - France (1)
   - Germany (2)
   - The United Kingdom (1)
   - Rest of Europe (3)
Asia-Pacific (Excluding Japan) (6)

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2228060/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Peripheral Arterial Disease (PAD) Therapeutics - Global Strategic Business Report
Web Address: http://www.researchandmarkets.com/reports/2228060/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>☐</td>
<td>USD 4950</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users</td>
<td>☐</td>
<td>USD 6930</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 10 Users</td>
<td>☐</td>
<td>USD 9405</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 15 Users</td>
<td>☐</td>
<td>USD 11880</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:  You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check:  Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer:  Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp